Insight Molecular Diagnostics (IMDX) Asset Utilization Ratio (2020 - 2025)
Historic Asset Utilization Ratio for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 0.09.
- Insight Molecular Diagnostics' Asset Utilization Ratio rose 85270.78% to 0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.09, marking a year-over-year increase of 85270.78%. This contributed to the annual value of 0.03 for FY2024, which is 9913.13% up from last year.
- Insight Molecular Diagnostics' Asset Utilization Ratio amounted to 0.09 in Q3 2025, which was up 85270.78% from 0.08 recorded in Q2 2025.
- In the past 5 years, Insight Molecular Diagnostics' Asset Utilization Ratio registered a high of 0.09 during Q3 2025, and its lowest value of 0.01 during Q3 2024.
- Over the past 5 years, Insight Molecular Diagnostics' median Asset Utilization Ratio value was 0.03 (recorded in 2021), while the average stood at 0.04.
- As far as peak fluctuations go, Insight Molecular Diagnostics' Asset Utilization Ratio tumbled by 6699.86% in 2022, and later surged by 85270.78% in 2025.
- Over the past 5 years, Insight Molecular Diagnostics' Asset Utilization Ratio (Quarter) stood at 0.05 in 2021, then crashed by 67.0% to 0.02 in 2022, then increased by 23.51% to 0.02 in 2023, then surged by 85.98% to 0.04 in 2024, then skyrocketed by 160.89% to 0.09 in 2025.
- Its last three reported values are 0.09 in Q3 2025, 0.08 for Q2 2025, and 0.08 during Q1 2025.